Edward F Kreider1, Katharine J Bar2. 1. Perelman School of Medicine, University of Pennsylvania, Stemmler Hall Room 130-150, 3450 Hamilton Walk, Philadelphia, PA, 19104-6073, USA. 2. Perelman School of Medicine, University of Pennsylvania, 502D Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA, 19104‑0673, USA. bark@pennmedicine.upenn.edu.
Abstract
PURPOSE OF REVIEW: Despite suppressive antiretroviral therapy (ART), a viral reservoir persists in individuals living with HIV that can reignite systemic replication should treatment be interrupted. Understanding how HIV-1 persists through effective ART is essential to develop cure strategies to induce ART-free virus remission. RECENT FINDINGS: The HIV-1 reservoir resides in a pool of CD4-expressing cells as a range of viral species, a subset of which is genetically intact. Recent studies suggest that the reservoir on ART is highly dynamic, with expansion and contraction of virus-infected cells over time. Overall, the intact proviral reservoir declines faster than defective viruses, suggesting enhanced immune clearance or cellular turnover. Upon treatment interruption, rebound viruses demonstrate escape from adaptive and innate immune responses, implicating these selective pressures in restriction of virus reactivation. Cure strategies employing immunotherapy are poised to test whether host immune pressure can be augmented to enhance reservoir suppression or clearance. Alternatively, genomic engineering approaches are being applied to directly eliminate intact viruses and shrink the replication-competent virus pool. New evidence suggests host immunity exerts selective pressure on reservoir viruses and clears HIV-1 infected cells over years on ART. Efforts to build on the detectable, but insufficient, reservoir clearance via empiric testing in clinical trials will inform our understanding of mechanisms of viral persistence and the direction of future cure strategies.
PURPOSE OF REVIEW: Despite suppressive antiretroviral therapy (ART), a viral reservoir persists in individuals living with HIV that can reignite systemic replication should treatment be interrupted. Understanding how HIV-1 persists through effective ART is essential to develop cure strategies to induce ART-free virus remission. RECENT FINDINGS: The HIV-1 reservoir resides in a pool of CD4-expressing cells as a range of viral species, a subset of which is genetically intact. Recent studies suggest that the reservoir on ART is highly dynamic, with expansion and contraction of virus-infected cells over time. Overall, the intact proviral reservoir declines faster than defective viruses, suggesting enhanced immune clearance or cellular turnover. Upon treatment interruption, rebound viruses demonstrate escape from adaptive and innate immune responses, implicating these selective pressures in restriction of virus reactivation. Cure strategies employing immunotherapy are poised to test whether host immune pressure can be augmented to enhance reservoir suppression or clearance. Alternatively, genomic engineering approaches are being applied to directly eliminate intact viruses and shrink the replication-competent virus pool. New evidence suggests host immunity exerts selective pressure on reservoir viruses and clears HIV-1 infected cells over years on ART. Efforts to build on the detectable, but insufficient, reservoir clearance via empiric testing in clinical trials will inform our understanding of mechanisms of viral persistence and the direction of future cure strategies.
Authors: D Brenda Salantes; Yu Zheng; Felicity Mampe; Tuhina Srivastava; Subul Beg; Jun Lai; Jonathan Z Li; Randall L Tressler; Richard A Koup; James Hoxie; Mohamed Abdel-Mohsen; Scott Sherrill-Mix; Kevin McCormick; E Turner Overton; Frederic D Bushman; Gerald H Learn; Robert F Siliciano; Janet M Siliciano; Pablo Tebas; Katharine J Bar Journal: J Clin Invest Date: 2018-06-18 Impact factor: 14.808
Authors: Patrick S Sullivan; Anna Satcher Johnson; Elizabeth S Pembleton; Rob Stephenson; Amy C Justice; Keri N Althoff; Heather Bradley; Amanda D Castel; Alexandra M Oster; Eli S Rosenberg; Kenneth H Mayer; Chris Beyrer Journal: Lancet Date: 2021-02-19 Impact factor: 79.321
Authors: Alison J Rodger; Rebecca Lodwick; Mauro Schechter; Steven Deeks; Janaki Amin; Richard Gilson; Roger Paredes; Elzbieta Bakowska; Frederik N Engsig; Andrew Phillips Journal: AIDS Date: 2013-03-27 Impact factor: 4.177
Authors: Jonathan Z Li; Behzad Etemad; Hayat Ahmed; Evgenia Aga; Ronald J Bosch; John W Mellors; Daniel R Kuritzkes; Michael M Lederman; Michael Para; Rajesh T Gandhi Journal: AIDS Date: 2016-01-28 Impact factor: 4.177
Authors: Antoine Chaillon; Sara Gianella; Simon Dellicour; Stephen A Rawlings; Timothy E Schlub; Michelli Faria De Oliveira; Caroline Ignacio; Magali Porrachia; Bram Vrancken; Davey M Smith Journal: J Clin Invest Date: 2020-04-01 Impact factor: 14.808
Authors: Ya-Chi Ho; Liang Shan; Nina N Hosmane; Jeffrey Wang; Sarah B Laskey; Daniel I S Rosenbloom; Jun Lai; Joel N Blankson; Janet D Siliciano; Robert F Siliciano Journal: Cell Date: 2013-10-24 Impact factor: 41.582
Authors: Julia L Marcus; Wendy A Leyden; Stacey E Alexeeff; Alexandra N Anderson; Rulin C Hechter; Haihong Hu; Jennifer O Lam; William J Towner; Qing Yuan; Michael A Horberg; Michael J Silverberg Journal: JAMA Netw Open Date: 2020-06-01
Authors: Jord C Stam; Steven de Maat; Dorien de Jong; Mathia Arens; Fenna van Lint; Lavina Gharu; Mark H van Roosmalen; Rob C Roovers; Nika M Strokappe; Ralf Wagner; Alexander Kliche; Hans J de Haard; Paul M van Bergen En Henegouwen; Monique Nijhuis; C Theo Verrips Journal: Sci Rep Date: 2022-08-04 Impact factor: 4.996